Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm phase 3 study of oral LNP023 in complement inhibitor-naive adults with atypical hemolytic uremic syndrome
CTR20220832Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Iptacopan in atypical hemolytic uremic syndrome (aHUS), sponsored by Novartis. Started Oct 2022; status: completed.
02
Drugs
Iptacopan
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on CTR20220832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220832.